Guggenheim Maintains Buy on AbbVie, Raises Price Target to $288

Benzinga Newsdesk www.benzinga.com Positive 85.2%

Neg 0% Neu 0% Pos 85.2%

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $261 to $288.

Comments

No comments yet. Be the first!